Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernanda S Correia-Melo

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Neuropsychiatric Disease and Treatment|August 10, 2017
Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart reviewFernanda S Correia-Melo, Felipe C Argolo, Lucas Araújo-de-Freitas, et al.
Trends in Psychiatry and Psychotherapy|March 8, 2021
Psychometric properties the of Brazilian Portuguese version of Snaith-Hamilton Pleasure Scale (SHAPS)Ana Paula Jesus-Nunes, João Paulo Barreto Borges Coroa, Felipe Coelho Argolo, et al.
Journal of Clinical Psychopharmacology|June 21, 2022
Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic DepressionBreno Souza-Marques, Manuela Telles, Gustavo C Leal, et al.
Journal of Psychiatric Research|June 29, 2023
Arketamine for bipolar depression: Open-label, dose-escalation, pilot studyIgor D Bandeira, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Human Psychopharmacology|February 18, 2022
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depressionAna Paula Jesus-Nunes, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Journal of Psychiatric Research|May 15, 2021
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trialRodrigo P Mello, Mariana V F Echegaray, Ana Paula Jesus-Nunes, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|March 9, 2022
Suicide attempt, impulsivity, and exposure to trauma in college studentsSidnei B Lira, Flávia Vieira, Diogo E Cavalcanti, et al.
Trends in Psychiatry and Psychotherapy|December 14, 2021
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trialAna Teresa Caliman-Fontes, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Trends in Psychiatry and Psychotherapy|September 17, 2023
Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trialMariana V F Echegaray, Rodrigo P Mello, Guilherme M Magnavita, et al.
European Archives of Psychiatry and Clinical Neuroscience|February 21, 2020
Intravenous arketamine for treatment-resistant depression: open-label pilot studyGustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Neuropsychiatric Disease and Treatment|August 10, 2017
Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart reviewFernanda S Correia-Melo, Felipe C Argolo, Lucas Araújo-de-Freitas, et al.
Trends in Psychiatry and Psychotherapy|March 8, 2021
Psychometric properties the of Brazilian Portuguese version of Snaith-Hamilton Pleasure Scale (SHAPS)Ana Paula Jesus-Nunes, João Paulo Barreto Borges Coroa, Felipe Coelho Argolo, et al.
Journal of Clinical Psychopharmacology|June 21, 2022
Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic DepressionBreno Souza-Marques, Manuela Telles, Gustavo C Leal, et al.
Journal of Psychiatric Research|June 29, 2023
Arketamine for bipolar depression: Open-label, dose-escalation, pilot studyIgor D Bandeira, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Human Psychopharmacology|February 18, 2022
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depressionAna Paula Jesus-Nunes, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Journal of Psychiatric Research|May 15, 2021
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trialRodrigo P Mello, Mariana V F Echegaray, Ana Paula Jesus-Nunes, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|March 9, 2022
Suicide attempt, impulsivity, and exposure to trauma in college studentsSidnei B Lira, Flávia Vieira, Diogo E Cavalcanti, et al.
Trends in Psychiatry and Psychotherapy|December 14, 2021
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trialAna Teresa Caliman-Fontes, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Trends in Psychiatry and Psychotherapy|September 17, 2023
Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trialMariana V F Echegaray, Rodrigo P Mello, Guilherme M Magnavita, et al.
European Archives of Psychiatry and Clinical Neuroscience|February 21, 2020
Intravenous arketamine for treatment-resistant depression: open-label pilot studyGustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, et al.
Pageof 2